Voriconazole

Restricted
Restricted

C. diff Risk

Low

Oral Bioavailability

Excellent

Approximate Cost

Dosing

PO - 400mg PO q12h x 2 doses then 200mg PO q12h

IV - 6mg/kg IV q12h x 2 doses then 4mg/kg IV q12h

Dose reduction may be required if low body weight

Requires approval by Infectious Diseases

Severe impairment (Child-Pugh C)
Should only be used if benefit outweighs risk

Mild to moderate (Child-Pugh A/B)
Standard loading dose then reduce maintenance by 50%

This antimicrobial is restricted to Infectious Diseases

General Information

Common Usage

Candida infections both mucocutaneous and invasive - i.e. Candidemia.

Antifungal prophylaxis in immunocompromised patients.

Drug Monitoring

Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (Discuss with ID).

QTc interval in patients at elevated risk.

Monitor hepatic profile.

Adverse Effects

  • Drug interactions

  • QTc prolongation

  • Hepatic enzyme abnormalities

  • Rash - up to 20%

  • Visual disturbance

  • Fluorosis

  • ¬†GI upset

Major Interactions

CYP450 interactions ++.

Other QTc prolonging agents.

Recommend review of pt medications due to high frequency of significant interactions.

Pharmacology

Antimicrobial class: Triazole antifungal, Second generation

Pregnancy category: D

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Poor